Financials
Financial year 2025
Worth noting
- A loss two years in a row.
Gross margin
€ -912,088
▲ 36% vs 2024
Profit
Caution€ -824,565
▲ 83% vs 2024
Debts
Low€ 48,128
▼ 24% vs 2024
Newton Biocapital II from Sint-Pieters-Woluwe, company number BE0779335513, closed financial year 2025 with a result of € -824,565 after tax. For that financial year Newton Biocapital II recorded a gross margin of € -912,088 and equity of € 24.6 million. Compared with financial year 2024, the result moved from € -4.8 million to € -824,565. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 1, 2026.
What happened at Newton Biocapital II?
What happened at Newton Biocapital II in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- DAB MANAGEMENT SRL stepped down as director. NBB
- SPARAXIS SA stepped down as director. NBB
- SUNATHIM SRL stepped down as director. NBB
- SFPIM SA stepped down as director. NBB
- SMS INVESTMENTS SA stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 824,565. Source: NBB ↗
- New establishment in Sint-Pieters-Woluwe. KBO
- Start of the company according to the CBE. KBO
In short
From € 1.5 million loss in 2022 to € 824,565 loss in 2025.
Paid € 583 in corporate taxes since 2022.
A new publication or filing at Newton Biocapital II? We notify you, reason included.
Follow Newton Biocapital IINeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
It owns 57.5% of TENSEGRITY PHARMA, 27.7% of SANTERO THERAPEUTICS, 27.3% of ADIPOPHARMA, 16.9% of CELLAION and 3.3% of AUGUSTINE THERAPEUTICS itself.
Directors
According to the 2025 annual accounts
Director · represented by Dirk BOOGMANS
Also active at: C.S.M., ENERGY SOLUTIONS GROUP, Newton Biocapital I, pricaf privée de droit belge +3 more
since 2021 · until 2027
Director · represented by Sophie SAUVAGE
Also active at: C.P. Bourg, A.M.B., Jean Goldschmidt International +228 more
since 2021 · until 2027
Director · represented by Ajit SHETTY
Also active at: SOUDAL HOLDING, reMYND, Newton Biocapital I, pricaf privée de droit belge +1 more
since 2021 · until 2027
Director · represented by François FONTAINE
Also active at: Aviapartner Belgium, Société Anonyme Belge de Constructions Aéronautiques, Société Nationale de Construction Aérospatiale +62 more
since 2021 · until 2027
Director · represented by Peter SEILER
since 2021 · until 2027
Establishments
Establishment units
Physical locations of this company
Tervurenlaan 273
1150 Sint-Pieters-Woluwe
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 21 companies are registered at this address.
BELGIAN RISK MANAGEMENT ASSOCIATION
European Coil Coating Association
€ 877,191 revenue · 2025
FEDERATION EUROPEENNE DE RISK MANAGEMENT - FEDERATION OF EUROPEAN RISK MANAGEMENT ASSOCIATIONS
€ 3.2 million revenue · 2024
LATOUR & PETIT
€ 1.5 million gross margin · 2025
AQ PARTNERS
€ 69,850 gross margin · 2025
+16 more
Details
- Company number
- 0779.335.513
- VAT number
- BE 0779.335.513
- Registered office
- Tervurenlaan 273, 1150 Sint-Pieters-Woluwe
- Names & denominations
- Newton Biocapital II
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 24 December 2021
- Peppol
- Active · Active since 27 Mar 2026